Repurposing ciclopirox as a pharmacological chaperone in a model of congenital erythropoietic porphyria

Pedro Urquiza,Ana Laín,Arantza Sanz-Parra,Jorge Moreno,Ganeko Bernardo-Seisdedos,Pierre Dubus,Esperanza González,Virginia Gutiérrez-de-Juan,Sandra García,Hasier Eraña,Itxaso San Juan,Iratxe Macías,Fredj Ben Bdira,Paula Pluta,Gabriel Ortega,Julen Oyarzábal,Rosario González-Muñiz,Juan Rodríguez-Cuesta,Juan Anguita,Emilio Díez,Jean-Marc Blouin,Hubert de Verneuil,José M Mato,Emmanuel Richard,Juan M Falcón-Pérez,Joaquín Castilla,Oscar Millet,José M. Mato,Juan M. Falcón-Pérez
DOI: https://doi.org/10.1126/scitranslmed.aat7467
IF: 17.1
2018-09-19
Science Translational Medicine
Abstract:The off-patent marketed antifungal ciclopirox improves symptoms in a mouse model of congenital erythropoietic porphyria.
cell biology,medicine, research & experimental
What problem does this paper attempt to address?